FedEx Corp. FDX – Options Review
Despite having signaled our options idea FDX on Tuesday morning, it was a postmarket drop, thus, leading into yesterday’s session, the earnings were still untraded upon. We reminded readers yesterday morning to look out for what we expected to be a solid performance, and we were not wrong.
Our sole target, the FDX Weekly $237.50 Calls ran from a low of 7.95 all the way up to 19.00 for us, which mean our idea has been good for a gain of up to 139% to this point.
With the markets flailing and looking to be set up for a lackluster day, we are going to open things up today and track a few sets of bearish options ideas for the SPY, AAPL, and NKE chains.
SPY Weekly $335-333 Puts
AAPL Weekly $111.25-108.75 Puts
NKE Weekly $118-117 Puts
PPCB, VNUE, TSOI, CLHI, HENC, CETY
3-Pack of Options Ideas
This morning we want offer up trio of fresh options ideas to track through this week, with some high profile earnings plays as well as a target in the SPY. Stocks in general are looking solid today, so the wind is blowing in the proper direction for it for the time being.
In addition to the SPY, we are looking at opportunities in the ADBE and FDX chains. Both companies are not slated to drop their quarterlies until after market hours, so we’ll be watching these in the run-up to that, and presumably for the remainder of the week after they present their figures.
Here are the specific targets we are interested in tracking:
SPY 09/16 $340-342 Calls
FDX Weekly $237.50 Calls
ADBE Weekly $490-495 Calls
BBRW, NWBO, OPTI, RBII, PFMS
Conagra Brands, Inc. CAG – Recap
With the markets ripping again yesterday, one of the options ideas we had zeroed in on produced some really nice gain opportunities for us. We signaled the CAG 07/02 $33.50-34.50 Calls, and two out of three of those contracts logged double-bag gains on the day.
Here are the total ranges and possible profits that these calls provided:
CAG 07/02 $33.50-34.50 Calls
$33.50: 1.15-2.15 (+87%)
$34: .77-1.76 (+129%)
$34.50: .55-1.35 (+145%)
FDX 07/02 $149-155 Calls
STZ 07/02 $175-180 Calls
OncoCyte Corp. OCX
On OCX yesterday, we noticed a drastic change as the stock fell off a cliff on news that it would discontinue development of its DetermaDx liquid biopsy test. Purely from a technical perspective, we have to take notice when a stock gets chopped by half and falls to near annual lows in one session.
It leaves a lot of future opportunity for a bounceback on the table, so we’re going to signal a long term idea in the options chain, and begin monitoring the OCX 11/20 $2.50 Calls.
ERFB, ARGQ, LFER, PVHO, XALL